223 related articles for article (PubMed ID: 36189319)
21. The recent advances of PD-1 and PD-L1 checkpoint signaling inhibition for breast cancer immunotherapy.
Setordzi P; Chang X; Liu Z; Wu Y; Zuo D
Eur J Pharmacol; 2021 Mar; 895():173867. PubMed ID: 33460617
[TBL] [Abstract][Full Text] [Related]
22. Integrated Analysis of RNA Binding Protein-Related lncRNA Prognostic Signature for Breast Cancer Patients.
Xu S; Xie J; Zhou Y; Liu H; Wang Y; Li Z
Genes (Basel); 2022 Feb; 13(2):. PubMed ID: 35205391
[TBL] [Abstract][Full Text] [Related]
23. Development of a novel hypoxia-immune-related LncRNA risk signature for predicting the prognosis and immunotherapy response of colorectal cancer.
Luan L; Dai Y; Shen T; Yang C; Chen Z; Liu S; Jia J; Li Z; Fang S; Qiu H; Cheng X; Yang Z
Front Immunol; 2022; 13():951455. PubMed ID: 36189298
[TBL] [Abstract][Full Text] [Related]
24. Construction of an immune-related lncRNA signature as a novel prognosis biomarker for LUAD.
Chen H; Shen W; Ni S; Sang M; Wu S; Mu Y; Liu K; Li N; Zhu L; Xu G
Aging (Albany NY); 2021 Aug; 13(16):20684-20697. PubMed ID: 34438369
[TBL] [Abstract][Full Text] [Related]
25. Immune Infiltration Subtypes Characterization and Identification of Prognosis-Related lncRNAs in Adenocarcinoma of the Esophagogastric Junction.
Hu X; Wu L; Liu B; Chen K
Front Immunol; 2021; 12():651056. PubMed ID: 34122409
[TBL] [Abstract][Full Text] [Related]
26. An immune risk score with potential implications in prognosis and immunotherapy of metastatic melanoma.
Sheng Y; Tong L; Geyu L
Int Immunopharmacol; 2020 Nov; 88():106921. PubMed ID: 32871477
[TBL] [Abstract][Full Text] [Related]
27. A Novel Prognostic Ferroptosis-Related lncRNA Signature Associated with Immune Landscape in Invasive Breast Cancer.
Shen S; Yang D; Yang Y; Chen Y; Xiong J; Hu X
Dis Markers; 2022; 2022():9168556. PubMed ID: 35359880
[TBL] [Abstract][Full Text] [Related]
28. Identification of a five-lncRNA signature for predicting the risk of tumor recurrence in patients with breast cancer.
Li J; Wang W; Xia P; Wan L; Zhang L; Yu L; Wang L; Chen X; Xiao Y; Xu C
Int J Cancer; 2018 Nov; 143(9):2150-2160. PubMed ID: 29707762
[TBL] [Abstract][Full Text] [Related]
29. Association of Long Noncoding RNA Biomarkers With Clinical Immune Subtype and Prediction of Immunotherapy Response in Patients With Cancer.
Yu Y; Zhang W; Li A; Chen Y; Ou Q; He Z; Zhang Y; Liu R; Yao H; Song E
JAMA Netw Open; 2020 Apr; 3(4):e202149. PubMed ID: 32259264
[TBL] [Abstract][Full Text] [Related]
30. Identification of CD4
Ning S; Wu J; Pan Y; Qiao K; Li L; Huang Q
Front Immunol; 2022; 13():880769. PubMed ID: 35603183
[TBL] [Abstract][Full Text] [Related]
31. Ferroptosis-related lncRNA signature predicts prognosis and immunotherapy efficacy in cutaneous melanoma.
Xu Y; Chen Y; Niu Z; Yang Z; Xing J; Yin X; Guo L; Zhang Q; Yang Y; Han Y
Front Surg; 2022; 9():860806. PubMed ID: 35937602
[TBL] [Abstract][Full Text] [Related]
32. The role of lncRNAs and circRNAs in the PD-1/PD-L1 pathway in cancer immunotherapy.
Jiang W; Pan S; Chen X; Wang ZW; Zhu X
Mol Cancer; 2021 Sep; 20(1):116. PubMed ID: 34496886
[TBL] [Abstract][Full Text] [Related]
33. Identification and verification of an immune-related lncRNA signature for predicting the prognosis of patients with bladder cancer.
Wang J; Shen C; Dong D; Zhong X; Wang Y; Yang X
Int Immunopharmacol; 2021 Jan; 90():107146. PubMed ID: 33189610
[TBL] [Abstract][Full Text] [Related]
34. Identification of pyroptosis-related lncRNAs for constructing a prognostic model and their correlation with immune infiltration in breast cancer.
Lv W; Tan Y; Zhao C; Wang Y; Wu M; Wu Y; Ren Y; Zhang Q
J Cell Mol Med; 2021 Nov; 25(22):10403-10417. PubMed ID: 34632690
[TBL] [Abstract][Full Text] [Related]
35. Cross-Talk Between m
Song W; Ren J; Xiang R; Yuan W; Fu T
Front Immunol; 2022; 13():740960. PubMed ID: 35350786
[TBL] [Abstract][Full Text] [Related]
36. Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies.
Pérez-Ruiz E; Melero I; Kopecka J; Sarmento-Ribeiro AB; García-Aranda M; De Las Rivas J
Drug Resist Updat; 2020 Dec; 53():100718. PubMed ID: 32736034
[TBL] [Abstract][Full Text] [Related]
37. Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma.
Zhao Z; He B; Cai Q; Zhang P; Peng X; Zhang Y; Xie H; Wang X
Int Immunopharmacol; 2021 Sep; 98():107807. PubMed ID: 34175739
[TBL] [Abstract][Full Text] [Related]
38. Blockade of PD-1, PD-L1, and TIM-3 Altered Distinct Immune- and Cancer-Related Signaling Pathways in the Transcriptome of Human Breast Cancer Explants.
Saleh R; Toor SM; Al-Ali D; Sasidharan Nair V; Elkord E
Genes (Basel); 2020 Jun; 11(6):. PubMed ID: 32616706
[TBL] [Abstract][Full Text] [Related]
39. Identification and Validation of a Three Pyroptosis-Related lncRNA Signature for Prognosis Prediction in Lung Adenocarcinoma.
Liu J; Liu Q; Shen H; Liu Y; Wang Y; Wang G; Du J
Front Genet; 2022; 13():838624. PubMed ID: 35928454
[TBL] [Abstract][Full Text] [Related]
40. Identification of Five m6A-Related lncRNA Genes as Prognostic Markers for Endometrial Cancer Based on TCGA Database.
Shan L; Lu Y; Xiang CC; Zhu X; Zuo ED; Cheng X
J Immunol Res; 2022; 2022():2547029. PubMed ID: 35571565
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
